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ABSTRACT
Background & Aims: Excess liver iron content is common and is linked to hepatic 
and extrahepatic disease risk. We aimed to identify genetic variants influencing liver 
iron content and use genetics to understand its link to other traits and diseases.
Methods: First, we performed a genome-wide association study (GWAS) in 8,289 
individuals in UK Biobank with MRI quantified liver iron, and validated our findings in 
an independent cohort (n=1,513 from IMI DIRECT). Second, we used Mendelian 
randomisation to test the causal effects of 29 predominantly metabolic traits on liver 
iron content. Third, we tested phenome-wide associations between liver iron variants 
and 770 anthropometric traits and diseases.   
Results: We identified three independent genetic variants (rs1800562 (C282Y) and 
rs1799945 (H63D) in HFE and rs855791 (V736A) in TMPRSS6) associated with liver 
iron content that reached the GWAS significance threshold (p < 5x10-8). The two 
HFE variants account for ~85% of all cases of hereditary haemochromatosis.  
Mendelian randomisation analysis provided evidence that higher central obesity 
plays a causal role in increased liver iron content. Phenome-wide association 
analysis demonstrated shared aetiopathogenic mechanisms for elevated liver iron, 
high blood pressure, cirrhosis, malignancies, neuropsychiatric and rheumatological 
conditions, while also highlighting inverse associations with anaemias, lipidaemias 
and ischaemic heart disease. 
Conclusion: Our study provides genetic evidence that mechanisms underlying 
higher liver iron content are likely systemic rather than organ specific, that higher 
  
central obesity is causally associated with higher liver iron, and that liver iron shares 
common aetiology with multiple metabolic and non-metabolic diseases. 
  
Lay summary: Excess liver iron content is common and is associated with liver 
diseases and metabolic diseases including diabetes, high blood pressure, and heart 
disease. We find that three genetic variants are linked to increased risk of developing 
higher liver iron content. We show that the same genetic variants are linked to higher 
risk of many diseases, but they may also be associated with some health 
advantages. Finally, we use genetic variants associated with waist-to-hip ratio as a 
tool to show that central obesity is causally associated with increased liver iron 
content. 
  
INTRODUCTION
Liver disease constitutes the third most common cause of premature death in the 
UK, and its prevalence is substantially higher compared to other countries in 
Western Europe.[1–3] Excess liver iron is associated with increased severity and 
progression of liver diseases including cirrhosis and hepatocellular carcinoma in 
individuals with non-alcoholic fatty liver disease (NAFLD), [4–6] and is the direct 
cause of liver disease in those with hereditary haemochromatosis and 
thalassaemia.[7,8] Observational associations have been described between excess 
liver iron content and several metabolic diseases such as high blood pressure, 
obesity, polycystic ovarian syndrome and type 2 diabetes - a condition recognised as 
dysmetabolic iron overload syndrome (DIOS) which affects up to 5-10% of the 
general population.[9,10]
The associations between excess liver iron and hepatic and non-hepatic diseases 
necessitate exploration of underlying pathophysiological mechanisms. Studies of 
hereditary haemochromatosis patients with autosomal recessive mutations show 
they have higher liver iron, measured from biopsies, when compared to controls, 
however no studies have been performed in unselected populations. Furthermore, it 
is unknown whether iron accumulation is a systemic disorder involving multiple 
organs or whether there are mechanisms specific to the liver. Previous genome-wide 
association studies (GWAS) have focussed on peripheral biochemical markers of 
iron status that do not correlate well with liver iron.[11]
Measuring liver iron has traditionally been difficult. Liver biopsy, the “gold standard” 
for assessment of liver iron, is an invasive procedure and therefore unsuitable for 
population research studies. An alternative is magnetic resonance imaging (MRI); a 
  
non-invasive, quick, robust and validated method for quantifying liver iron 
content.[12] The availability of genetic and clinical data, as well as MRI scans of liver 
in the UK Biobank cohort has provided an unparalleled opportunity to study the 
genetics of liver iron content in the general population. 
The aim of this study was to (i) identify genetic variants specifically associated with 
liver iron content, (ii) investigate which metabolic traits and diseases might cause 
higher liver iron content, and (iii) characterise the traits/diseases associated with liver 
iron content susceptibility variants. To facilitate this, we performed the first GWAS of 
MRI-determined liver iron content in 8,289 UK Biobank participants and replicated 
our findings in an independent cohort of 1,513 participants of European ancestry 
from the IMI DIRECT study (Figure 1).[13,14]
  
METHODS
UK Biobank participants
UK Biobank consists of over 500,000 individuals aged 37–73 years (99.5% were 
between 40 and 69 years of age) who were recruited between 2006 and 2010 from 
across the U.K.[13] This research has been conducted using the data obtained via 
UK Biobank Access Application number 9914. UK Biobank field numbers used for 
this analysis can be found in Supplementary Table 1. We used data from the first 
subset of UK Biobank participants invited for multiparametric MRI imaging between 
2014 and 2016.[15] After image analysis and quality control steps (see below), liver 
iron was available for 8,674 individuals who also had genetic data. We based our 
study on 8,289 individuals of white European descent as defined by principal 
component (PC) analysis. Briefly, we first generated PCs in the 1000 Genomes 
cohort using high-confidence SNPs to obtain their individual loadings. We then used 
these loadings to project all the UK Biobank samples into the same PC space, and 
individuals were clustered using PCs 1–4.
Genetic Data
Protocols for the participant genotyping, data collection, and quality control have 
previously been described in detail.[13] Briefly, participants were genotyped using 
one of two purpose-designed arrays (UK BiLEVE Axiom Array (n= 50,520) and UK 
Biobank Axiom Array (n = 438,692)) with 95% marker overlap. We excluded 
individuals who were identified by the UK Biobank as outliers based on either 
genotyping missingness rate or heterogeneity, or whose sex inferred from the 
genotypes did not match their self-reported sex. We removed individuals with a 
  
missingness >5% across variants which passed our quality control procedure. We 
used the latest release which included imputed data using two reference panels: a 
combined UK10K and 1000 Genomes panel and the Haplotype Reference 
Consortium (HRC) panel. We limited our analysis to genetic variants with a minimum 
minor allele frequency (MAF) > 1% and imputation quality score (INFO) > 0.3. 
Imaging protocol and analysis
The imaging protocol and analysis of liver iron content in UK Biobank participants 
has previously been published.[15] Briefly, participants were scanned at the UK 
Biobank centre in Cheadle (UK) using a Siemens 1.5T Magnetom Aera. A single-
breath-hold MRI sequence was acquired as a single transverse slice captured 
through the centre of the liver, superior to the porta hepatis. This sequence forms 
part of the UK Biobank abdominal imaging protocol. The data was analysed using 
the LiverMultiScan™. Discover software by a team of trained analysts, blinded to any 
subject variables. Analysts selected three 15mm diameter circular regions of 
interests, to cover a representative sample of the liver parenchyma, avoiding 
vessels, bile ducts and other organs. The repeatability and reproducibility of the 
image analysis was high.[15]
Genome-wide association analysis
We performed the association tests using 2 different software: (1) GEMMA version 
0.96 as our main analysis using all individuals of genetically defined Europeans 
(n=8,289),[16] and (2) PLINK version 1.9 as our sensitivity analysis using unrelated 
white British individuals (defined in UK Biobank field 22006, n=6,758).[17]
  
GEMMA applies a linear mixed-model (LMM) to adjust for the effects of population 
structure and relatedness. Therefore, we increased our power by including all related 
individuals of European descent. The relatedness matrix was computed using 
common (MAF>5%) genotyped variants that passed quality control. Prior to 
association testing, liver iron was first log-transformed and then adjusted for age, sex 
and study centre and in our sensitivity analysis additionally for BMI or alcohol 
consumption. We then inverse normal transformed the values. At runtime, we 
included genotyping array (as a categorical variable for UKBileve array, UKB Axiom 
array interim release and UKB Axiom array full release) as a covariate.
We used PLINK to perform a sensitivity analysis. Prior to association testing, liver 
iron was adjusted for age, sex, BMI and genotyping array, and then we quantile 
normalised the resulting values. At runtime, we included the first 10 genetic PCs (UK 
Biobank field 22009) as covariates to control for confounding by population 
stratification. We used Quanto (http://biostats.usc.edu/Quanto.html) to calculate our 
discovery GWAS power in 8,289 individuals from UK Biobank at different allele 
frequencies and effect sizes at α level 5×10−8 assuming additive effect model 
(Supplementary Figure 1).
LD Score regression and cross-trait genetic correlation analysis
We used LDHub to conduct linkage disequilibrium (LD) score regression and 
heritability analysis. LD Hub is a centralized database of summary level GWAS for > 
100 diseases/traits from publicly available resources/consortia and uses a web 
interface that automates LD score regression, heritability and cross-trait genetic 
correlation analysis pipeline.[18] We ran heritability analysis as well as genetic 
  
correlation analysis across 448 potentially relevant traits. SNP-based heritability 
(h2SNP) is the proportion of total variation in liver iron content due to the additive 
genetic variation between individuals in our study population.
Gene-set and tissue expression enrichment analysis 
We performed gene-set and tissue expression analyses using MAGMA.[19] Lead 
variants were assigned to a minimum p value of 5x10-8. We used the default settings 
provided by the software. We chose 1000 Genomes Phase 3 as the reference panel 
population. The minimum minor allele frequency was set to 0.01. We used a 
maximum allowed distance of 250k between LD blocks for variants to be included in 
the same locus. 
For gene-set enrichment analyses, positional mapping was used with variants 
assigned to a gene if they were within the gene start and end points (by setting the 
distance either side to 0kb). Only protein-coding genes were included in the mapping 
process. Tested gene-sets include BioCarta, REACTOME, KEGG and GO. 
Bonferroni correction was used to adjust for the number of gene-sets tested. 
Analysis of differentially expressed genes were based on data from GTEx v6 RNA-
seq data.[20] 
Replication analysis
Associations reaching p < 5x10-8 were followed up in the IMI DIRECT cohort. IMI 
DIRECT includes 1,513 participants who had both liver iron and GWAS data to 
replicate our findings. The IMI-DIRECT consortium is a collaboration among 
investigators from a range of European academic institutions and pharmaceutical 
companies.[14] Liver iron was measured using a T2*-based multiecho MRI 
  
technique.[21] DNA extraction was carried out using Maxwell 16 Blood DNA 
purification kits and a Maxwell 16 semi-automated nucleic acid purification system 
(Promega). Genotyping was conducted using the Illumina HumanCore array (HCE24 
v1.0) and genotypes were called using Illumina’s GenCall algorithm. A total of 
517,958 markers passed quality control procedures. We took autosomal variants 
with MAF>1% that passed quality control and constructed axes of genetic variation 
using PC analysis implemented in the GCTA software to identify ethnic outliers 
defined as non-European ancestry using the 1000 Genomes samples as reference. 
We identified six individuals as ethnic outliers.
We performed the association tests in 3 models: (i) non-diabetic participants 
(n=1,010), (ii) diabetic participants (n=503), and (iii) combined (n=1,513). We took 
residuals from a model of liver iron and age, sex, BMI, 10 PCs and Centres and then 
inverse-normal transformed the values. 
Sensitivity Analyses
We performed 4 sensitivity analyses. First, to assess whether there is any sex-
specific association, we carried out GWASs in men and women separately. Second, 
to test whether relatedness was responsible for any of the individual variant 
associations and replicate GEMMA’s results, we ran a GWAS using only unrelated 
Europeans individuals in UK Biobank and a different GWAS software tool (PLINK 
version 1.9). Third, we adjusted models for alcohol intake frequency (field 1558; 
categories treated as ordinal scale – “Never”=0 to “Daily or almost daily”=5) 
measured at baseline that may have had an impact on liver iron. Individuals 
responding “Do not know” or “Prefer not to answer” for “Alcohol intake frequency” 
were excluded from this sensitivity analysis. Fourth, to investigate the potential for 
  
collider bias resulting from conditioning liver iron on BMI, we performed a GWAS of 
liver iron without adjustment for BMI. 
Mendelian randomisation
Multiple traits have shown association with liver iron in observational studies, 
including BMI, lipids and non-alcoholic fatty liver disease.[10,22–24] We therefore 
investigated the causal effects of 29 predominantly metabolic traits using two-sample 
Mendelian randomisation analysis.[25] Mendelian randomisation is a method that 
uses genetic variants associated with the exposure (e.g. metabolic traits) to infer 
causal relationships between an exposure and an outcome (e.g. liver iron content). 
This method relies on a simple principle; if a modifiable exposure is causal for a 
disease, then the genetic variants associated with that exposure will also be 
associated with disease risk. Since genetic variants are inherited at birth, Mendelian 
randomisation experiments are free from confounding and biases that are seen in 
observational studies. 
Following correction for multiple testing, associations with a false discovery rate 
(FDR) <5% were considered statistically significant. We used the inverse variance 
weighted approach (IVW) as our main analysis, and MR-Egger and penalised 
weighted median as sensitivity analyses in the event of unidentified pleiotropy of our 
genetic instruments. Genetic instruments for the 29 metabolic traits as an exposure 
were constructed by developing risk scores using only genome-wide significant 
SNPs that were not in linkage disequilibrium (R2 <0.1).[26–28]
Phenome-wide association study (PheWAS)
  
We used the SNPs associated with liver iron content and carried out a PheWAS 
using publicly available summary statistics from GWASs on predefined ICD10 
disease codes, anthropometric traits, and self-reported conditions previously carried 
out in 452,264 UK Biobank participants of European ancestry,[29] as well as publicly 
available, curated summary statistics from previous GWAS (Supplementary Tables 
2-4).[30] Associations with a false discovery rate (FDR) <5% were considered 
statistically significant. A description of how ICD codes were grouped to represent a 
clinical phenotype are provided elsewhere.[29] 
  
RESULTS
The characteristics of liver iron content cohort.
The median liver iron content in UK Biobank was 1.28 mg/g (interquartile range 
(IQR):1.16-1.44 mg/g) in men (n=3,928) and 1.23 mg/g (IQR: 1.13-1.38) in women 
(n=4,361) (Table 1, Supplementary Figure 2). Among men 6.5% and among 
women 3.4% had an elevated liver iron content, above the commonly accepted 
1.8mg/g threshold.[31] In IMI DIRECT cohort, the median liver iron content was 1.3 
(1.2-1.5) in both men (n=1,101) and women (n=412). BMI, waist circumference and 
diabetes prevalence were lower in the liver iron cohort (n=8,289) than the remainder 
of UK Biobank (n=402,071) (Supplementary Table 5). Although invitation was not 
based on any medical information, MRI exclusion criteria (e.g. metal or electrical 
implants, surgery in six weeks prior to appointment, severe hearing or breathing 
problems) may have also contributed to a slightly healthier cohort. The Townsend 
deprivation index was on average lower in this study cohort. This may be related to 
MRI participants being biased towards those who live close to the imaging center 
(Cheadle) where all of the liver iron cohort were imaged. 
There are three genetic variants associated with liver iron content. 
We performed a GWAS of MRI derived measures of liver iron using 8,289 individuals 
of European ancestry from UK Biobank (Figure 2, Supplementary Figure 3). We 
estimated to have more than 80% power in our discovery set to detect variants with 
MAF>=5% and effect size >= 0.2 standard deviation (SD) on liver iron content 
(Supplementary Figure 1). We detected no evidence for inflation of test statistics 
(λGC = 1.016). Our discovery GWAS identified 4 independent variants at p<5x10-8 
  
(Table 2). Two independent variants lie within HFE: C282Y (rs1800562; 0.41 SD 
increase in liver iron per allele; p=5.2x10-42) and H63D (rs1799945; 0.17 SD; 
p=8.2x10-15). The third variant lies in TMPRSS6; V736A (rs855791; 0.11 SD; 
p=1.3x10-11). The fourth variant, rs149275125, lies between HS3ST3B1 and PMP22 
(0.41 SD; p=3x10-9). 
In 1,513 IMI DIRECT participants, we replicated all three common variants at p < 
4x10-4 with a consistent direction of effect and similar effect size (Supplementary 
Table 6). The rare variant did not associate with liver iron in IMI DIRECT and the 
direction of effect was opposite to our discovery dataset. This variant is a rare variant 
(MAF 1%) and has not previously been reported to be associated with any other 
traits. We focused all other analyses on the three replicated variants.
Both HFE and TMPRSS6 produce proteins that form part of the signalling pathway 
regulating hepcidin production, the key hormone responsible for iron balance in the 
body. C282Y homozygotes and C282Y/H63D compound heterozygotes account for 
~85% of cases of hereditary haemochromatosis.[7] In UK Biobank, 35 individuals 
(0.4%) were C282Y homozygotes and had the highest levels of liver iron (mean: 
2.39 mg/g (±1.2)); 182 (2.2%) were C282Y/H63D compound heterozygotes (1.75 
mg/g (±0.7)); 186 (2.2%) were H63D homozygotes (1.46 mg/g (±0.47)); 2,920 (35%) 
were either C282Y or H63D heterozygotes (1.34 mg/g (±0.32)) and 4,966 (60%) did 
not have any of the variants and had the lowest liver iron (1.28 mg/g (±0.24)) (Figure 
3). 
Correlation between the effect sizes and p-values in the two separate GWASs 
carried out in GEMMA and PLINK showed strong agreement (Supplementary 
  
Figures 4, 5). We did not detect any sex-specific variants and the magnitude of 
effect was similar between men and women (Supplementary Table 6, 
Supplementary Figure 6). The sensitivity analysis adjusting for alcohol 
consumption and BMI did not identify any additional signal and did not change the 
effect size (Supplementary Table 6). Our pathway analysis demonstrates overlap 
between liver iron gene-sets and pathways involved in autism and schizophrenia 
(Supplementary Figure 7). Nearby genes were visualised with locuszoom plots 
(Supplementary Figures 8, 9)
Liver iron content is heritable and has a high genetic correlation with blood 
levels of iron biomarkers.
We estimated the SNP-based heritability (h2SNP) of liver iron to be 7%. This is similar 
to heritability estimated for conditions and traits such as coronary artery disease 
(7%)[32] and eczema (7%),[33] but lower than heritability estimated for body fat % 
(10%)[34] and transferrin (16%).[11] 
To identify genetic overlap between liver iron content and other diseases and traits, 
we performed LD score regression analyses against a range of available traits and 
diseases with GWAS summary statistics (448 traits/diseases, Supplementary Table 
7). The most genetically correlated traits were transferrin (rG=-0.78, p=0.04) and 
ferritin (rG=1.24, p=0.05) with nominal significant correlation. Joint disorders (rG=-
1.17, p=0.50), hypertrophic cardiomyopathy (rG=-1.11, p=0.35), type 2 diabetes 
(rG=0.44, p=0.17), chronic kidney disease (rG=0.57, p=0.48), tinnitus (rG=0.65, 
p=0.17), polyuria (rG=0.75, p=0.36), and gout (rG=0.90, p=0.19) were highly 
correlated (rG>0.4) but did not reach a nominal significance threshold (p>0.05). 
Metabolic traits including fasting insulin (rG=0.17, p=0.53), HOMA-IR (rG=0.37, 
  
p=0.48), fasting glucose (rG=0.01, p=0.97) and coronary artery disease (rG=-0.01, 
p=0.97) were not genetically correlated with liver iron content.
Gene-set enrichment analysis did not identify any enriched tissue or 
pathways.
We used MAGMA implemented as part of the FUMA GWAS platform to assess 
tissue enrichment of genes at associated loci. We did not find any tissue enrichment, 
but differentially expressed gene sets were enriched in blood vessels, lung, and 
adipose tissue, although they did not reach a significant threshold following 
adjustment for multiple testing (Supplementary Table 8). None of the pathways 
reached our FDR significance threshold (Supplementary Table 9). 
Mendelian randomisation analysis provides evidence for a causal link between 
central obesity and liver iron content.
We examined the potential causal effect of 29 metabolic traits and diseases (Figure 
4, Supplementary Table 10) on liver iron content. Following correction for multiple 
testing (FDR<5%), we found evidence of a causative effect of central obesity, as 
measured by higher waist-to-hip ratio (adjusted for BMI), on elevated liver iron 
content (IVW p=0.003) (Supplementary Table 9, Supplementary Figure 10). 
There was suggestive evidence that higher fasting glucose (IVW p=0.03), higher 
NAFLD (IVW p=0.04) and higher alanine transaminase (IVW p=0.05) were causally 
associated with higher liver iron content but none of these associations reached our 
multiple testing threshold of being statistically significant. All the results were robust 
to a range of Mendelian randomisation sensitivity analyses.
  
As a positive control, elevated transferrin saturation levels (IVW p=0.0007), blood 
iron content (IVW p=0.01) and ferritin levels (IVW p=0.01) were associated with 
higher liver iron content. The genetic variants (between 5 to 6 variants) associated 
with these serum iron parameters include the 3 variants associated with liver iron 
content (HFE C282Y, HFE H63D, TMPRSS6 V736A). Therefore, it was not possible 
to test the causal effect of these parameters on liver iron content independent of 
HFE and TMPRSS6 genetic variants.
PheWAS identifies novel associations of liver iron variants with traits and 
diseases. 
The three liver iron content variants had been previously reported to be associated 
with multiple haematological parameters, glycated haemoglobin, lipid and bilirubin 
levels, as well as blood pressure traits (Supplementary Table 11). We performed a 
hypothesis-free PheWAS to investigate the association of these three variants with 
other traits and diseases using predefined ICD10 codes, self-reported conditions and 
traits from UK Biobank and publicly available GWAS.
HFE C282Y was associated with higher liver fibrosis/cirrhosis, higher risk of type 2 
diabetes, hypertension, alcoholic liver disease, arthrosis, chronic and degenerative 
neurological conditions including multiple sclerosis, arthritis and higher height but 
lower total cholesterol, lower LDL-C and lower BMI (FDR<5%, Figure 5, 
Supplementary Table 2). HFE H63D was associated with higher risk of 
hypertension, ankylosing spondylitis and bladder malignancy but lower risk of 
malabsorption or coeliac disease and lower cognitive ability (FDR<5%, Figure 5, 
Supplementary Table 3). The liver iron increasing allele at TMPRSS6 was 
  
associated with lower risk of ischaemic heart disease, angina pectoris, and 
lipidaemias (FDR<5%, Figure 5, Supplementary Table 4).
  
DISCUSSION
We performed the first GWAS of multi-parametric MRI determined liver iron content 
in an unselected population. The identification of loci implicated in increased iron 
absorption (HFE and TMPRSS6) provides genetic validation of the utility of MRI for 
the non-invasive assessment of liver iron content. 
The three independent variants in HFE and TMPRSS6 have previously been 
reported to be associated with circulating iron traits including transferrin saturation, 
blood iron, ferritin, and transferrin levels.[11] Both HFE and TMPRSS6 play a major 
role in iron homeostasis by modulating the expression of hepcidin production by the 
liver.[35],[36] Hepcidin inhibits iron transport and absorption from the gut into the 
circulation by binding to the main iron transport channel expressed on the surface on 
duodenal enterocytes, ferroportin.[37] TMPRSS6 encodes matriptase 2 (MTP-2), a 
liver serine protease, which inhibits hepcidin leading to higher iron absorption and 
bioavailability. In vitro studies have shown that major allele at rs888571 inhibits 
hepcidin more effectively than missense variant rs888571(V736A).[38] HFE is a 
positive upstream regulator of hepcidin transcription. Missense variants C282Y and 
H63D in HFE result in lower hepcidin responsiveness to iron, leading to relative or 
absolute hepcidin deficiency and subsequent increase in iron absorption and 
bioavailability.[39]
Elevated liver iron is observationally associated with multiple metabolic traits and 
diseases in a common condition described as DIOS.[10] Our Mendelian 
randomisation analysis supports a causal role for higher central obesity on higher 
liver iron content, providing further evidence for DIOS. Other traits such as fasting 
glucose, NAFLD, and alanine transaminase showed suggestive causal associations. 
  
Animal studies have suggested a putative mechanism through defective iron 
handling and subsequent iron overload due to an inflammatory shift and cytokine 
secretion by activated macrophages that accumulate around adipocytes in 
obesity.[40,41] The underlying mechanism, however, is still unclear, and is likely to 
involve a complex interplay between diet and genetic factors as well as cross-talk 
between liver and visceral adipose tissue.[10] 
Our GWAS study identified variants that are likely to regulate iron stores systemically 
and are not specific to the liver. We, therefore, were not able to examine the causal 
role of higher liver iron content per se on other diseases and traits using Mendelian 
randomisation. To investigate, however, the phenotypic architecture and shared 
pathological mechanisms of higher liver iron content with other traits and diseases, 
we carried out a PheWAS of the 3 genome-wide significant variants against all 
available disease outcomes and traits from UK Biobank[29] and publicly available 
genetic summary statistics.[30] 
Our PheWAS indicates HFE C282Y is associated with arthrosis, coxarthrosis, 
osteoarthritis, and gout, and HFE H63D is associated with ankylosing spondylitis and 
has a suggestive association with dorsalgia. The association between HFE C282Y 
and higher risk of cellulitis, abscesses, furuncles and curbuncles, subcutaneous 
infections as well as osteomyelitis provides further evidence that genetically elevated 
iron levels are associated with higher infection risk. Some infectious disease agents 
are more virulent in an environment with excess iron. There is also evidence that iron 
overload compromises the ability of phagocytes to kill microorganisms.[42] 
Higher iron is correlated with carcinogenesis.[43] An important mechanism may be 
oxidative stress and the catalytic activity of iron in the formation of hydroxyl radicals. 
  
Iron may also suppress host defence cell activity and promote cancer cell 
proliferation. A recent study found an association between HFE C282Y and higher 
risk of breast cancer, colorectal cancer, hepatocellular carcinoma, and total cancer 
risk.[44] We found additional evidence of associations with extra-hepatic 
malignancies including bladder cancer (OR=1.0004 per copy of H63D, p=4.7x10-6, 
FDR 0.03) and renal cancer (OR=1.0005 per copy of C282Y, p=0.004, FDR 0.05). 
Despite very small effects, these findings provide genetic evidence for shared 
mechanisms underlying higher liver iron and extra-hepatic cancers. 
The association between HFE C282Y and neurological conditions such as multiple 
sclerosis and epilepsy is consistent with the role of iron in many important processes 
in the central nervous system, including oxygen transportation, oxidative 
phosphorylation, myelin production, and the synthesis and metabolism of 
neurotransmitters. In a recent GWAS of brain MRI scans, HFE C282Y was 
associated with iron accumulation in certain parts of the brain.[45] Observational 
studies show that iron accumulation in the brain is associated with multiple sclerosis, 
parkinsonism and Alzheimer’s disease.[46,47] Individuals with hereditary 
haemochromatosis frequently develop psychological symptoms, including extreme 
fatigue, irritability and depression.[48] Our pathway analysis demonstrates overlap 
with gene-sets and pathways involved in autism and schizophrenia. HFE H63D was 
associated with a reduction in reaction time in specific cognitive function tests, 
providing further evidence that iron accumulation may cause premature, and indeed 
preventable, cognitive decline. 
The association between HFE variants and hypertension is consistent with previous 
findings[49] Possible mechanisms include increased vascular tone secondary to the 
  
generation of reactive oxygen species and oxidative stress,[50] or excess iron 
accumulation in renal arterioles leading to activation of the renin-angiotensin 
aldosterone system. We further validated the known association between HFE 
C282Y and type 2 diabetes which could be, at least partly, due to iron accumulation 
in the pancreas. 
The liver iron increasing allele at TMPRSS6 rs855791 was associated with lower 
LDL-C, lower risk of angina and ischaemic heart disease. Similar observations have 
been reported in HFE C282Y homozygotes.[51] A Mendelian randomisation study 
has recently reported that elevated circulating iron may have a causal (protective) 
effect on coronary artery disease.[52] The underlying mechanism is unclear. It is 
possible that part of this effect is driven through effects on haematological 
parameters, or lower LDL-C. In conditions where excess iron stores are treated (e.g. 
hereditary haemochromatosis), further research is needed on whether LDL-C levels 
subsequently increase, and whether the risk of coronary artery disease can be kept 
low with statins and other preventive interventions.[51] 
This study is limited in that the UK Biobank MRI cohort is not a completely unbiased 
sample of the population. The UK Biobank MRI cohort is slightly more healthy, 
wealthy, and well educated compared to the whole cohort of 40-69 year olds in the 
UK.[53] The population studied in this work has a slightly lower average BMI and 
waist circumference than the UK Biobank population as a whole. Larger GWAS 
studies (e.g. on completion of the full 100,000 UK Biobank imaging cohort) may 
elucidate further susceptibility loci. Ongoing development and validation of MRI 
scores that may allow accurate determination of the level of inflammation and 
  
fibrosis, may lead to further genetic studies focussing on the more severe spectrum 
of liver disease. 
Conclusion
We report a large GWAS for MRI liver iron content and identify 3 susceptibility loci 
previously linked with circulating iron traits. We provide genetic validation for multi-
parametric MRI as a novel, non-invasive and radiation free imaging modality for liver 
iron content. Our genetic study suggests that higher liver iron content may be caused 
in part by higher central adiposity.  The deposition of excess iron in the liver seems 
to share common mechanisms with circulating iron accumulation, which eventually 
results in widespread damage to parenchymal tissue, leading to several pathologies 
through a common mechanism.
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Figure 1. Study design. GWAS on liver iron content was performed in UK Biobank 
(N = 8,289) and replicated in IMI DIRECT (N = 1,115).  
Figure 2. Manhattan plot illustrating genetic variants (~30 million imputed 
SNPs) associated with liver iron in UK Biobank. The x-axis is the chromosomal 
position and y axis is -log(P) for the association with each variant. Black line 
indicates genome-wide significance level (5 x 10-8).
Figure 3.  Liver iron content per genotype group. X-axis are the 6 genotypes 
groups based on the number of C282Y and H63D they carry. Y-axis is the mean of 
liver iron (mg/g) per category. Error bars indicate 95% confidence intervals. Numbers 
in brackets are the number of individuals per genotype category.
Figure 4. The effect of 25 predominantly metabolic traits and diseases on liver 
iron content (standard deviation (SD)). The plot illustrates per allele effect of 
genetic variants associated with different metabolic traits. We have used alleles 
associated with higher adiposity, higher metabolic disease risk, higher glycaemic 
traits, adverse lipid levels, higher liver enzymes and adverse metabolic biomarkers 
profile. For comparison, the plot illustrates the effect of HFE C282Y, HFE H63D, 
TMPRSS6 V736A on liver iron content. Please refer to Supplementary Table 10 for 
the results of two-sample Mendelian randomisation analysis including 4 circulating 
iron biomarkers. The error bars indicate 95% confidence intervals.
Figure 5. Illustration of prioritised associations following phenome-wide 
association studies (PheWAS) of rs1800562, rs1799945 and rs855791 and 
significant traits from UK Biobank and publicly available summary statistics. 
Blue indicates a positive association and red an inverse association, following 
  
correction for multiple testing (False discovery rate < 5%). Continuous traits betas 
were scaled to per SD where appropriate for better visualisation. Effect on disease 
risk is given in log(odds ratio).
Table 1. Characteristics of UK Biobank and IMI DIRECT study participants.
Characteristics UK Biobank liver iron cohort DIRECT
Men Women Men Women
N (%) 3,928 4,361 1,101 412
age (IQR) 
(years)
57 (51,62) 56 (49,61) 62 (56,66) 62 (57,67)
Liver iron (IQR) 
(mg/g)
1.28 
(1.16,1.44)
1.23 
(1.13,1.38)
1.3 
(1.2, 1.5)
1.3 
(1.2, 1.5)
Waist Circumference 
(IQR) (cm)
94 (88, 101) 80 (74, 89) 101 (95,109) 97 (88,108)
Townsend deprivation 
index (IQR)
-2.72 
(-3.95, -0.76)
-2.63 
(-3.87,-0.80)
NA NA
Self reported 
diabetes (%)
134 (3.7%) 88 (2.2%) 287 (26%) 216 (52.4%)
BMI (IQR) 
(kg/m2)
26.49 
(24.3, 29)
25.08 
(22.59,28.35)
27.8 
(25.8, 30.5)
28.7 
(25.8,33.2)
No consuming 
alcohol daily (%) 
1,088 (27.7%) 825 (18.9%) 129(15.6%) 25(10.7%)
*N = Number, IQR = interquartile range
  
Table 2. Genome-wide significant independent variants associated with MRI liver 
iron content in UK Biobank (p < 5 x10-8) and validation in IMI DIRECT.
UK Biobank             
(N = 8,289)
DIRECT 
(N = 1,513).
Non-
Finnish 
Europeans 
*
SNP Gene Chr EA OA EAF BETA SE P EAF BETA SE P EAF
rs1800562 HFE 6 A G 0.08 0.41 0.03 5.2x10
-42
0.04 0.35 0.08 5x10-5 0.06
rs1799945 HFE 6 G C 0.15 0.16 0.02 8.2x10
-15
0.12 0.19 0.05 2x10-4 0.14
rs855791 TMPRSS6 22 G A 0.56 0.11 0.02 1.3x10
-11
0.59 0.12 0.04 4x10-4 0.56
rs149275125 HS3ST3B1--
--[]----
PMP22
17 C T 0.98 0.41 0.07 3.1x10
-9
0.99 -.22 0.2 0.27 0.99
Chr = chromosome, EA = effect allele, OA = other allele, EAF = effect allele 
frequency, Beta = per allele effect on liver iron (SD), SE = standard error, P = p- 
value.
* Data from The Genome Aggregation Database (gnomAD; 
https://gnomad.broadinstitute.org). 
Highlights
1) Variants in HFE and TMPRSS6 are associated with higher liver iron
2) There is genetic evidence that higher central obesity causes higher liver iron
3) Higher liver iron variants are not organ specific and associate with multiple 
diseases.
